**Core tip:** This nationwide prospective survey in Japan evaluated the clinical characteristics of complicated erosive esophagitis (EE) and its associated factors at the time of proton pump inhibitors (PPIs) availability in real-world clinical settings. Our results indicate that aging and severe EE were common associated factors, although there were more associated factors in esophageal strictures than esophageal ulcer bleeding, indicating that pathophysiology of esophageal strictures was more complex than esophageal ulcer bleeding. Despite the availability and widespread use of PPIs, EE complications are likely to remain a problem in Japan owing to the aging population and high-stress society.

INTRODUCTION
============

The prevalence of erosive esophagitis (EE) was previously considered much lower in Asian countries, including Japan, than in Western countries\[[@B1]\]. In recent years, however, the prevalence of EE has increased in Japan\[[@B2],[@B3]\]. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and mortality rates\[[@B4]\].

Because reflux of acidic gastric contents into the esophagus plays a major role in the pathogenesis of EE, acid suppression is currently the most effective therapeutic approach. During the last two decades, many pharmacological studies and large clinical trials have shown the superiority of proton pump inhibitors (PPIs) over other drugs, including antacids, prokinetics, and H~2~-receptor antagonists\[[@B5]\]. PPIs are now considered the mainstay of anti-reflux treatment and are extensively prescribed, not only by gastroenterologists and general practitioners but also by non-GI specialists\[[@B6]\]. Although the ready availability and widespread use of PPIs have altered the presentation of complicated EE, little is known about its epidemiology. This nationwide prospective survey in Japan therefore evaluated the frequency of complicated EE and its associated factors at the time of PPI availability in real-world clinical settings.

MATERIALS AND METHODS
=====================

Study design
------------

This multicenter, prospective, cross-sectional survey was conducted between October 2014 and March 2015 by members of the Gastroesophageal Reflux Disease (GERD) Society, a Japanese GERD study group, at 106 centers located throughout Japan. These centers included 26 university hospitals, 76 public hospitals, and four national hospitals. This study included all patients with a final diagnosis of EE. The demographic and clinical characteristics of these patients were evaluated, including medical history, general condition, gastrointestinal (GI) symptoms, lifestyle habits, comorbidities, and endoscopic findings. Each hospital recorded detailed information on EE patients and sent this information to a central database. This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research issued by the Ministry of Health, Labour and Welfare of Japan, and was approved by the ethics committee of each center and of Kawasaki Medical School, Kurashiki, Japan (Study Number: 1883). This study was registered at the University Hospital Medical Information Network (UMIN registration ID: UMIN000014157).

Inclusion and exclusion criteria
--------------------------------

All consecutive patients aged ≥ 50 years with a final diagnosis of EE were enrolled in this study. EE was defined as mucosal breaks on the esophagus and categorized as Los Angeles (LA) classification grades A, B, C and D\[[@B7]\]. All included patients provided written informed consent. EE patients were excluded if they had a history of malignancy, GI resection, gastrostomy, or endoscopic resection (including endoscopic mucosal resection or endoscopic submucosal dissection).

Endoscopic findings
-------------------

EE-related complications, including esophageal ulcer bleeding, strictures, and perforation, were recorded. The endoscopic extent of gastric mucosal atrophy was classified as described\[[@B8]\]. Long-segment Barrett's esophagus was diagnosed by endoscopic identification of columnar epithelium extending more than 3 cm into the esophagus without histological evidence of intestinal metaplasia. Concurrent findings during endoscopy, such as hiatus hernia, gastritis, or gastroduodenal ulcers were also recorded. The judging panel consisted of four endoscopic specialists (KH, TJ, KN, and KI) qualified by the Japan Gastroenterological Endoscopy Society made the final diagnosis of EE complications. If the panel could not reach a consensus diagnosis on EE-related complications, the patient in question was excluded from those with EE-related complications (Figure [1](#F1){ref-type="fig"}).

![Endoscopic images of typical cases with erosive esophagitis-related complications. A and C: Esophageal stricture with ulcer bleeding; B and D: Esophageal stricture with ulcer.](WJG-23-318-g001){#F1}

Data collection
---------------

Each doctor who participated in this research study conducted face-to-face interviews with all participants using a questionnaire made for this study. Information obtained *via* the questionnaire included patient characteristics, EE treatment, concomitant drugs, comorbidities, and lifestyle, including alcohol consumption, smoking status, and general condition (nasogastric feeding, bedridden, or both). Other patient characteristics included sex, age, height, body weight, and GI symptoms at the time of the endoscopy. Height and body weight were used to calculate body mass index. Reflux symptoms were based on patient reports of heartburn and acid regurgitation. If patients complained of reflux symptoms, the duration of each symptom was determined. Upper GI symptoms were based on patient reports of epigastric pain, epigastric burning, heavy stomach feeling, and early satiety. Lower GI symptoms were based on patient reports of abdominal fullness, constipation, and diarrhea. Infection with *Helicobacter pylori* (*H. pylori*) was defined as at least one positive result on the following tests: histology, culture, rapid urease tests using endoscopic biopsy specimens, *H. pylori*-specific antibody in patient serum, urea breathing test, or stool antigen test. Patients were classified as never smokers, ex-smokers or current smokers. Regarding alcohol intake, patients were classified as never drinkers, ex-drinkers or current drinkers. Patients classified as current drinkers were subclassified by weekly frequency of drinking as less than once, two to four times, or five or more times.

End-points
----------

The primary end-point was the clinical characteristics of patients with EE-related complications, including esophageal ulcer bleeding and strictures. The secondary end-point was to clarify the factors associated with complicated EE.

Statistical analysis
--------------------

Continuous variables are reported as mean and SD, whereas categorical variables are reported as percentages. Student's *t*-tests were used to compare two independent groups. The *χ*^2^ test (with Yates correction, if required) was used to compare percentages. Logistic regression analysis was used to calculate odds ratios (ORs) and 95%CIs for the association with complications of EE. Multivariate logistic regression analysis included all factors determined by univariate analysis to be associated with complications. OR was regarded as an estimate of the relative risk of factors associated with complicated EE. Statistical significance was defined at *P* \< 0.05. All statistical analyses were performed using JMP 12.0.1 and SAS 9.4 (SAS Institute, Cary, NC, United States).

RESULTS
=======

Participant description
-----------------------

During the study period between October 2014 and March 2015, 1817 were diagnosed with EE. Of them, 68 (3.7%) were excluded for the following reasons: age \< 50 years (61 patients), insufficient data (four patients), history of GI surgery (two patients), and lack of esophageal mucosal breaks (one patient). The study cohort therefore consisted of 1749 participants (1044 men and 705 women, mean age 68.0 ± 9.6). Of these patients, 995, 508, 162, and 84 were diagnosed with LA grades A, B, C, and D, respectively. Of the 1,749 patients with EE, 143 (8.2%) had complications, including 84 (4.8%) with esophageal ulcer bleeding, 45 (2.6%) with esophageal strictures, and 14 (0.8%) with both.

Clinical characteristics in EE patients with and without complications
----------------------------------------------------------------------

Table [1](#T1){ref-type="table"} shows the clinical characteristics of the 143 EE patients with complications and the 1606 without complications. The presence of complications was associated with older age, female sex, and being bedridden. The percentage of EE patients with reflux-related symptoms was higher in patients who had complications than in those without complications (Table [2](#T2){ref-type="table"}), although their duration of heartburn symptoms did not differ significantly (*P =* 0.226). Other GI symptoms, including epigastric pain, epigastric burning, and constipation, were more frequent in EE patients with than without complications (Table [2](#T2){ref-type="table"}). There were a higher percentage of current drinkers (two to four times per week frequency) among patients with uncomplicated EE than with complicated EE. Smoking status did not differ significantly in these two groups (Table [1](#T1){ref-type="table"}). Patients with EE complications had more severe EE on endoscopy than those without complications (Table [3](#T3){ref-type="table"}). The frequency of endoscopic gastric mucosal atrophy, defined by the Kimura-Takemoto classification (C1-O3), was similar in the two groups. The rates of hiatal hernia and Barrett's epithelium were higher in patients with than without EE-related complications. Assessments of comorbidities showed that cerebral infarction, dementia, and kyphosis occurred more frequently in EE patients with than without complications (Table [1](#T1){ref-type="table"}), and that patients with complications used more antiplatelet agents (except aspirin), non-steroidal anti-inflammatory drugs, and psychoactive drugs. PPI prescribing differed significantly in the two groups, although previous history of EE did not (Table [1](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of erosive esophagitis patients with and without complications *n* (%)

                                                                   **With complications (*n* = 143)**   **Without complications (*n* = 1606)**   ***P* value**
  ---------------------------------------------------------------- ------------------------------------ ---------------------------------------- ---------------
  Sex (M/F)                                                        74/69                                970/636                                  0.043
  Age (years old)                                                  74.4 ± 11.0                          67.4 ± 9.2                               \< 0.001
  BMI (kg/m^2^)                                                    23.2 ± 3.8                           23.8 ± 3.5                               0.074
  General condition (tube-fed/bedridden/tube-fed + bedridden)      0/8/0                                1/5/1                                    \< 0.001
  Consultation behavior (outpatient/inpatient/emergency patient)   90/26/27                             1511/83/12                               \< 0.001
  Smoking (never/current smoker/ex-smoker)                         94/16/33                             955/234/417                              0.311
  Duration of smoking cessation (yr)                               16.8 ± 13.7                          14.5 ± 13.3                              0.359
  Alcohol drinking                                                                                                                               \< 0.001
  Never                                                            76 (53.1)                            711 (44.3)                               
  Current                                                                                                                                        
  \< 1 d per week                                                  10 (7.0)                             199 (12.4)                               
  2-4 d per week                                                   4 (2.8)                              192 (12.0)                               
  \> 5 d per week                                                  38 (26.6)                            432 (26.9)                               
  Ex-drinker                                                       15 (10.5)                            72 (4.5)                                 
  Duration of drinking cessation (yr)                              8.8 ± 9.7                            9.0 ± 10.8                               0.957
  Comorbidities                                                                                                                                  
  Hypertension                                                     71 (49.7)                            724 (45.1)                               0.293
  Diabetes mellitus                                                26 (18.2)                            282 (17.6)                               0.851
  Hyperlipidemia                                                   33 (23.1)                            391 (24.3)                               0.734
  Cerebrovascular disease                                          22 (15.4)                            83 (5.2)                                 \< 0.001
  Liver cirrhosis                                                  4 (2.8)                              30 (1.9)                                 0.441
  Ischemic cardiac disease                                         13 (9.1)                             85 (5.3)                                 0.058
  Collagen disease                                                 6 (4.2)                              34 (2.1)                                 0.111
  Dementia                                                         13 (9.1)                             11 (0.7)                                 \< 0.001
  Kyphosis                                                         11 (7.7)                             36 (2.2)                                 \< 0.001
  PPI treatment status                                                                                                                           0.001
  Never                                                            20 (27.4)                            395 (50.4)                               
  Continuation therapy                                             40 (54.8)                            251 (32.1)                               
  On-demand therapy                                                2 (2.7)                              35 (4.5)                                 
  Cessation                                                        11(15.1)                             102 (13.0)                               
  Concomitant medication                                                                                                                         
  Antithrombogenic                                                 31 (21.7)                            216 (13.5)                               0.007
  Aspirin                                                          12 (8.4)                             97 (6.0)                                 0.265
  Antiplatelet agent                                               15 (10.5)                            89 (5.5)                                 0.017
  Anticoagulant agent                                              8 (5.6)                              60 (3.7)                                 0.271
  Antihypertensive drug                                            58 (40.6)                            615 (38.3)                               0.594
  NSAID                                                            17 (11.9)                            91 (5.7)                                 0.003
  Psychotropic                                                     16 (11.2)                            40 (2.5)                                 \< 0.001

BMI: Body mass index; PPI: Proton pump inhibitor; NSAID: Nonsteroidal antiinflammatory drug.

###### 

Symptoms at the time of endoscopy of erosive esophagitis patients with and without complications *n* (%)

                          **With complications (*n* = 143)**   **Without complications (*n* = 1606)**   ***P* value**
  ----------------------- ------------------------------------ ---------------------------------------- ---------------
  Upper GI symptoms                                                                                     
  Heartburn               86 (60.1)                            773 (48.1)                               0.006
  Regurgitation           54 (37.8)                            428 (26.7)                               0.004
  Epigastric pain         34 (23.8)                            261 (16.3)                               0.022
  Epigastric burning      28 (19.6)                            149 (9.3)                                \< 0.001
  Heavy stomach feeling   42 (29.4)                            398 (24.8)                               0.227
  Early satiety           19 (13.3)                            136 (8.5)                                0.052
  Lower GI symptoms                                                                                     
  Abdominal Bloating      10 (7.0)                             165 (10.3)                               0.210
  Constipation            39 (27.3)                            277 (17.2)                               0.003
  Diarrhea                7 (4.9)                              117 (7.3)                                0.286
  Constipation/diarrhea   5 (3.5)                              39 (2.4)                                 0.434

GI: Gastrointestinal.

###### 

Endoscopic findings of erosive esophagitis patients with and without complications *n* (%)

                               **With complications (*n* = 143)**   **Without complications (*n* = 1606)**   ***P* value**
  ---------------------------- ------------------------------------ ---------------------------------------- ---------------
  Los Angeles classification                                                                                 \< 0.001
  A                            19 (13.3)                            976 (60.8)                               
  B                            30 (21.0)                            478 (29.8)                               
  C                            43 (30.1)                            119 (7.4)                                
  D                            51 (35.7)                            33 (2.1)                                 
  Gastric mucosal atrophy      82 (57.3)                            930 (57.9)                               0.464
  Hiatal hernia                123 (86.0)                           1070 (66.6)                              \< 0.001
  Barrett's epithelium         8 (5.6)                              24 (1.5)                                 \< 0.001
  *H. pylori* infection                                                                                      \< 0.001
  Positive                     10 (7.0)                             134 (8.3)                                
  Negative                     31 (21.7)                            677 (42.2)                               
  Unknown                      102 (71.3)                           795 (49.5)                               

*H. pylori*: *Helicobacter pylori*.

Factors associated with complications of EE
-------------------------------------------

Multivariate logistic regression analysis was used to determine the factors associated with EE complications. Six factors were found to be significantly and independently associated with complications: increased age \[adjusted odds ratio (aOR): 1.05; 95%CI: 1.03-1.08, *P \<* 0.001\], concomitant use of psychotropic agents (aOR: 6.51; 95%CI: 3.01-13.61, *P \<* 0.001), and LA grades B (aOR: 2.69; 95%CI: 1.48-4.96, *P =* 0.001), C (aOR: 15.38; 95%CI: 8.62-28.37, *P \<* 0.001) and D (aOR: 71.49; 95%CI: 37.47-142.01, *P \<* 0.001). In contrast, consumption of alcohol two to four times per week showed a significant negative association with EE complications (aOR: 0.23; 95%CI: 0.06-0.61, *P =* 0.008) (Table [4](#T4){ref-type="table"}).

###### 

Relative risk for complications of erosive esophagitis (multivariable analysis)

                                               **Odds ratio (95%CI)**   ***P* value**
  -------------------------------------------- ------------------------ ---------------
  Ages                                         1.05 (1.03-1.08)         \< 0.001
  Alcohol drinking                                                      
  Never                                        1.00                     \-
  \< 1 d per week                              0.73 (0.32-1.52)         0.425
  2-4 d per week                               0.23 (0.06-0.61)         0.008
  \> 5 d per week                              1.32 (0.80-2.14)         0.268
  Concomitant medication: psychotropic agent   6.51 (3.01-13.61)        \< 0.001
  Los Angeles classification grade                                      
  A                                            1.00                     \-
  B                                            2.69 (1.48-4.96)         0.001
  C                                            15.38 (8.62-28.37)       \< 0.001
  D                                            71.49 (37.47-142.01)     \< 0.001

Factors associated with esophageal ulcer bleeding
-------------------------------------------------

Multivariate logistic regression analysis was used to determine the factors associated with esophageal ulcer bleeding. Four factors were found to be significantly and independently associated with complications: increased age (aOR: 1.05; 95%CI: 1.02-1.07, *P \<* 0.001), LA grades B (aOR: 3.60; 95%CI: 1.52-8.50, *P =* 0.004), C (aOR: 27.61; 95%CI: 12.34-61.80, *P \<* 0.001) and D (aOR: 119.09; 95%CI: 51.15-277.29, *P \<* 0.001).

Factors associated with esophageal strictures
---------------------------------------------

Multivariate logistic regression analysis was used to determine the factors associated with esophageal strictures. Seven factors were found to be significantly and independently associated with complications: increased age (aOR: 1.07; 95%CI: 1.04-1.10, *P \<* 0.001), reflux-related symptoms (aOR: 2.51; 95%CI: 1.39-4.51, *P =* 0.002), concomitant use of psychotropic agents (aOR: 11.79; 95%CI: 5.06-27.48, *P \<* 0.001), and LA grades C (aOR: 7.35; 95%CI: 3.32-16.25, *P \<* 0.001), D (aOR: 20.34; 95%CI: 8.36-49.53, *P \<* 0.001) and long-segment Barrett's esophagus (aOR: 4.63; 95%CI: 1.64-13.05, *P =* 0.004).

DISCUSSION
==========

This Japanese, multicenter, prospective, cross-sectional study involving 1749 patients with EE, 38.3% of whom were prescribed PPIs, showed that 8.2% of these patients had complications, including 4.8% with esophageal ulcer bleeding, 2.6% with esophageal strictures, and 0.8% with both. On multivariate analysis, increased age, concomitant use of psychotropic agents, and severe EE as defined by LA grades B-D was significantly associated with complications. Interestingly, moderate alcohol consumption showed a significant negative association with complications in patients with EE. Although several studies have evaluated risk factors for EE\[[@B9],[@B10]\], this study, to our knowledge, is the first multicenter large-scale study to assess factors associated with complicated EE among Japanese patients, the majority of whom were being treated with PPIs.

Obesity, smoking, and age are risk factors for EE\[[@B11]-[@B16]\], with age also being considered an important risk factor for severe EE\[[@B17]-[@B19]\]. Age is associated with increased esophageal exposure to acid, although the severity of reflux symptoms decreases with age. These changes are associated with a progressive decrease in abdominal lower esophageal sphincter (LES) length and esophageal motility\[[@B18]\]. Increasing EE severity in elderly subjects, such as esophageal ulcer bleeding or stricture, is related to degradation of the gastroesophageal junction and impaired esophageal clearance. Interestingly, this study also found that concomitant treatment with psychotropic agents was an independently associated factor for complicated EE. Long-term use of psychotropic agents, such as clozapine and clomipramine, has been associated with severe esophageal dilation and hypomotility accompanied by lowered visceral sensitivity, leading to excess esophageal exposure to acid and impaired acid clearance, which are considered crucial causes of complicated EE\[[@B20]\]. Nevertheless, psychotropic agents differed in the ability to influence the pathophysiology of EE\[[@B21],[@B22]\]. This study, however, did not evaluate the relationships of complicated EE with the duration of use or the type of psychotropic agents, suggesting the need for further studies to clarify these points.

Because the reflux of acidic gastric content into the esophagus leads to symptoms and esophageal mucosal breaks, acid suppression is considered the most effective therapeutic approach, with PPIs being superior to other classes of drug\[[@B5]\]. PPIs are now considered the mainstay of anti-reflux therapy and are extensively prescribed worldwide. This study found that patients with complicated EE were more likely to be prescribed a PPI than those without complications. Considering the previous studies showing that PPI-resistant EE is observed more frequently in patients with severe EE than those with mild EE\[[@B23],[@B24]\], it may be the case that patients with PPI-resistant EE tend to also have complications.

This study also found that moderate alcohol drinking was significantly negatively associated with complicated EE. Although this study did not clarify whether the moderate alcohol drinking was a cause or result of complicated EE, several studies have shown that consumption of large amounts of alcohol can promote regurgitation of acid into the esophagus, thereby causing EE, which is inconsistent with our result\[[@B25],[@B26]\]. Several other studies examining the risk of EE in relation to alcohol consumption have yielded contradictory outcomes. For example, alcohol use has been reported to be a risk factor for EE\[[@B27]\], but its long-term effects and relationship to pathological reflux have not been determined. Other studies, however, have suggested that alcohol exposure was not associated with the risk of EE\[[@B28]\]. EE was recently reported to be significantly associated with psychosocial stress, with the severity of EE correlating with the degree of stress\[[@B29]\]. Moderate amounts of alcohol may reduce psychosocial stress\[[@B30]\], explaining the mechanism underlying the negative relationship between moderate alcohol drinking and complicated EE. Additional physiological studies are necessary to assess the influence of moderate amounts of alcohol on the mechanism of EE in more detail.

Analyzing associated factors with each EE complication separately revealed that aging and severe EE were common associated factors, which is consistent with previous studies\[[@B31],[@B32]\]. In this study we also found that there were more associated factors in esophageal strictures than esophageal ulcer bleeding, indicating that pathophysiology of esophageal strictures was more complex than esophageal ulcer bleeding.

This study had three limitations. First, information about patients' diets was not recorded, even though chocolate and other high-fat foods have been reported to increase the likelihood of EE\[[@B33]\]. However, the impact of diet on EE was not the focus of this study. Second, this study did not evaluate the rate of drug adherence/compliance\[[@B34]\]. Rather, we focused on characteristics of complicated EE, based on current Japanese clinical guidelines. Further studies will therefore be necessary to clarify these matters. Third, not only body mass index but also upper arm anthropometry and grip strength are important in the assessment of general nutritional status\[[@B35]\]. Because we only evaluated general nutritional status with body mass index, further study is necessary to clarify this matter.

In conclusion, the aging of the Japanese population and increasing levels of stress associated with daily life in modern Japan will likely lead to increased rates of EE and associated complications, despite the availability and widespread use of PPIs.
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